阻断白介素-17治疗银屑病:PsoPlus队列的真实世界经验
在比利时根特大学医院银屑病门诊开展的真实世界研究,纳入111例患者共134个IL-17抑制剂疗程。维持期97.0%和77%分别达到接近完全和完全皮损清除,总体药物生存期69.0个月,生物制剂初治者药物生存期高于经治者(p=0.011)。
要点
- IL-17抑制剂在真实世界中高效,维持期97.0%达接近完全清除、77%达完全清除。
- 治疗调整主因为应答不佳(63.0%),以换药(25.4%)和剂量升级(11.9%)为主。
- 生物制剂初治者药物生存期高于经治者(p=0.011),依奇珠单抗倾向生存期最高。
核心结论
- 真实世界研究显示IL-17抑制剂是银屑病非常有效的药物,依奇珠单抗为领先生物制剂。
- 既往生物制剂暴露似乎影响IL-17抑制剂药物生存期。
- 治疗调整主要在应答不足时进行,以换药和剂量升级为主,依奇珠单抗患者最少见。
- 谷浓度可能使临床决策更合理,但需要标准化算法来证实其使用。
研究设计与样本
- 数据来自比利时根特大学医院皮肤科PsoPlus门诊接受IL-17抑制剂治疗的银屑病患者。
- 共纳入111例患者,计134个IL-17抑制剂疗程(司库奇尤单抗、依奇珠单抗和布罗达鲁单抗)。
- 采用描述性统计和Kaplan-Meier分析。
主要发现
- 55%的患者在启动IL-17抑制剂前为生物制剂初治。
- 维持期97.0%和77%分别达到接近完全和完全皮损清除。
- 治疗调整的主要原因是不佳应答(63.0%)和安全性问题(9.3%)。
- 报告的调整方式为换药(25.4%)、剂量升级(11.9%)、剂量降级(6.7%)、联合治疗(6.0%)和停用IL-17抑制剂(3.0%)。
- 总体药物生存期为69.0个月,不同IL-17抑制剂间无差异(p=0.078),依奇珠单抗倾向生存期最高;生物制剂初治者药物生存期高于经治者(p=0.011)。
关键数值与推荐
- 20例患者测量了谷浓度并事后解读,85%的临床决策与谷浓度一致(如证实需要剂量升级)。
- 其余病例中,若当时已知谷浓度则会导向另一临床决策。
临床怎么用
- 本研究中心的做法是测量IL-17抑制剂谷浓度并事后解读,85%的临床决策与谷浓度一致。
- 作者认为谷浓度可能使临床决策更合理,但需要标准化算法来证实其使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world studies on the use of biologics in psoriasis (Pso) are increasing, but still scarce. Trough concentrations (Ct s) of interleukin-17 inhibitors (IL-17i) seem promising for clinical decision-making, but their value in daily practice has yet to be proven. OBJECTIVES: To report on IL-17i effectiveness, treatment modifications and Ct use in our clinic. METHODS: Data were collected from IL-17i-treated Pso patients followed up in the PsoPlus clinic at the Dermatology department, Ghent University Hospital, Belgium. Descriptive statistics and Kaplan-Meier analysis were performed. RESULTS: A total of 111 patients were included, counting for 134 IL-17i courses (secukinumab, ixekizumab, and brodalumab). Fifty-five per cent of the patients were bio-naive prior to IL-17i initiation. During maintenance, merely 97.0% and 77% achieved near-complete and complete skin clearance, respectively. Major reasons for treatment modification were suboptimal response (63.0%) and safety issues (9.3%). Reported modifications were switch (25.4%), dose escalation (11.9%), dose de-escalation (6.7%), treatment association (6.0%) and IL-17i stop (3.0%). Overall drug survival was 69.0 months, without difference between the different IL-17i (p = 0.078). Ixekizumab tended to have the highest survival. Drug survival was higher in bio-naive subjects compared to bio-experienced subjects (p = 0.011). Ct was measured in 20 patients and interpreted post hoc. In 85%, the clinical decision was in accordance with the Ct (e.g. substantiated need for dose escalation). For the other cases, the Ct would have led to another clinical decision if known at that time. CONCLUSIONS: This real-world study showed that IL-17i are very effective drugs for Pso, with ixekizumab as leading biologic. Prior bio-experience seemed to impact IL-17i drug survival. Treatment modifications were mainly performed in case of insufficient response, primarily via switch and dose escalation, and least frequently in ixekizumab patients. Ct might rationalize clinical decision-making; however, there is need for standardized algorithms to corroborate its use.
引用
- Schots L, Soenen R, Blanquart B, et al. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort. J Eur Acad Dermatol Venereol. 2023. PMID: 36562700. doi:10.1111/jdv.18827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。